Results 11 to 20 of about 97,405 (387)
Therapeutic Advances in Chronic Disease, 2019 Background: Inhaled levodopa may quickly resolve off periods in Parkinson’s disease. Our aim was to determine the pharmacokinetics and tolerability of a new levodopa dry-powder inhaler.
Marianne Luinstra +9 more
doaj +2 more sources
Levodopa-Induced Changes in Electromyographic Patterns in Patients with Advanced Parkinson’s Disease [PDF]
Frontiers in Neurology, 2018 Levodopa medication is the most efficient treatment for motor symptoms of Parkinson’s disease (PD). Levodopa significantly alleviates rigidity, rest tremor, and bradykinesia in PD.
Verneri Ruonala +5 more
doaj +4 more sources
Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals
Movement Disorders, 2023 To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed.
S. Jost +27 more
semanticscholar +1 more source
Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease
European Journal of Neurology, 2023 Levodopa is the gold standard for the symptomatic treatment of Parkinson's disease (PD). There are well documented motor and non‐motor fluctuations, however, that occur almost inevitably once levodopa is started after a variable period in people with PD.
V. Leta +13 more
semanticscholar +1 more source
Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies
Cells, 2022 The most commonly used treatment for Parkinson’s disease (PD) is levodopa, prescribed in conjunction with carbidopa. Virtually all patients with PD undergo dopamine replacement therapy using levodopa during the course of the disease’s progression ...
Destany K. Kwon +3 more
semanticscholar +1 more source
Mechanisms of peripheral levodopa resistance in Parkinson’s disease
npj Parkinson's Disease, 2022 Parkinson’s disease (PD) is an increasingly common neurodegenerative condition. The disease has a significant negative impact on quality of life, but a personalized management approach can help reduce disability. Pharmacotherapy with levodopa remains the
Milan Beckers, B. Bloem, M. Verbeek
semanticscholar +1 more source
A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa [PDF]
New England Journal of Medicine, 2000 Olivier Rascol +5 more
openalex +2 more sources
Advances in Nutrition, 2021 Although levodopa remains the most effective drug for symptomatic management of Parkinson's Disease (PD), treatment during advanced disease stages may raise unpredictable motor fluctuations and other complications.
Jikke T Boelens Keun +3 more
semanticscholar +1 more source
Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide
Movement Disorders Clinical Practice, 2020 There has been a steadily growing armamentarium of drugs for the symptomatic treatment of Parkinson’s disease (PD). Consequently, as various various pharmaceutical agents are used, it has become more difficult to perform and compare clinical trials with ...
Sebastian Schade +2 more
semanticscholar +1 more source
npj Parkinson's Disease, 2023 The relationship between dopaminergic treatment and freezing of gait (FOG) in Parkinson’s disease (PD) is complex: levodopa is the most effective symptomatic treatment for FOG, but long-term pulsatile levodopa treatment has also been linked to an ...
Jamie A. F. Jansen +6 more
doaj +1 more source